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Summary
The majority of cancer-related deaths are associated with metastasis; however, little is known about the mechanisms of
this process. Hepsin is a cell surface serine protease that is markedly upregulated in human prostate cancer; however,
the functional significance of this upregulation is unknown. We report here that hepsin overexpression in prostate epithelium
in vivo causes disorganization of the basement membrane. Overexpression of hepsin in a mouse model of nonmetastasizing
prostate cancer has no impact on cell proliferation, but causes disorganization of the basement membrane and promotes
primary prostate cancer progression and metastasis to liver, lung, and bone. We provide in vivo evidence that upregulation
of a cell surface serine protease in a primary tumor promotes cancer progression and metastasis.
Introduction Several recent DNA microarray studies of gene expression
in human prostate carcinomas have revealed marked overex-
pression of hepsin, a type II transmembrane serine proteaseExtracellular and cell surface proteases play an important role
in development and normal tissue homeostasis (Werb et al., (Chen et al., 2003; Dhanasekaran et al., 2001; Ernst et al., 2002;
Luo et al., 2001; Magee et al., 2001; Stamey et al., 2001; Stephan1999). In addition, these enzymes are believed to be especially
important during the final stages of primary tumor progression, et al., 2004; Welsh et al., 2001). Hepsin mRNA is upregulated
in 90% of prostate tumors, with levels often increased10 fold,invasion, and metastasis. It is hypothesized that they are in-
volved in the cleavage of extracellular matrix proteins to allow and exclusively expressed in tumor cells. Upregulation of hepsin
RNA levels was accompanied by an increase in protein levelstumor cells to invade the connective tissues, blood, and lymph
vessels and subsequently travel out of the vasculature to distant (Dhanasekaran et al., 2001). It is not clear how hepsin mRNA
levels correlate with different stages/grades of prostate cancer.sites. While multiple types of proteases are involved in these
activities, most of the attention in previous years has been de- Although initial studies showed that hepsin levels were highest
in prostatic intraepithelial neoplasia (PIN) and decrease withvoted to the matrix metalloproteinases (MMPs) (Chang and
Werb, 2001). In addition to MMPs, serine proteases have been prostate cancer progression (Dhanasekaran et al., 2001), other
studies have demonstrated that hepsin mRNA levels increaseimplicated in degradation of the extracellular matrix and modula-
tion of cell-substratum adhesion in tumor cells (Del Rosso et with prostate cancer progression and reach maximum levels in
more advanced (Gleason grade 4/5) prostate carcinomas (Chenal., 2002). Type II transmembrane serine proteases represent a
specialized group of cell surface proteolytic enzymes (Hooper et al., 2003; Stamey et al., 2001). At present, it is unclear if
overexpression of hepsin in prostate cancer cells plays a roleet al., 2001). The C-terminal serine protease domain of these
proteins is localized at the cell surface and interacts with extra- in prostate cancer development or progression, and what mech-
anisms may be responsible for this role.cellular matrix components and transmembrane molecules. The
N-terminal cytoplasmic domain associates with intracellular To determine the role of hepsin in prostate epithelium in vivo,
we generated and analyzed probasin promoter-driven hepsinmolecules and participates in signaling. While the functional role
of these enzymes is largely unknown, interest in these molecules transgenic mice (PB-hepsin). We found that hepsin overexpres-
sion causes weakening of epithelial-stromal adhesion. Immuno-stems from observations that they are often overexpressed in
cancer. fluorescent staining and electron microscopy revealed the disor-
S I G N I F I C A N C E
Knowledge about the mechanisms responsible for metastasis is pivotal for development of efficient therapies to combat cancer.
Here we demonstrate that hepsin, a cell surface protease that is markedly upregulated in human prostate cancer, promotes prostate
cancer progression and metastasis. Upregulation of hepsin causes disorganization and disruption of the prostate basement membrane,
and this may be the mechanism by which hepsin promotes metastasis. Our findings suggest that the development of therapeutic
approaches to specifically inhibit hepsin proteolytic activity may provide a valuable tool to decrease metastasis in prostate cancer
patients.
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Figure 1. Generation of transgenic mice overex-
pressing hepsin in prostate epithelium
A: Schematic representation of probasin-hepsin
(PB-hepsin) transgene.
B: The PB-hepsin transgenic construct produces
hepsin protein in a prostate carcinoma cell line.
The empty vector or PB-hepsin construct was
transiently transfected into LNCaP cells and total
protein extracts were analyzed by Western blot
with anti-hepsin antibodies.
C: The PB-hepsin transgenic mouse lines C and
D express hepsin mRNA in the prostate gland.
Total RNA was extracted from the prostate
glands of 10-week-old control (control) and
transgenic (lines A–D) mice and analyzed by
Northern blot hybridization using hepsin and
GAPDH probes.
D: Ventral prostate-specific expression of the PB-
hepsin transgene. Total RNA was extracted from
indicated prostate lobes and organs of 21-week-
old PB-hepsin animals (line C and D) and ana-
lyzed by Northern blot hybridization with GFP
(Hepsin-IRES-GFP) and 18S RNA probes.
E and E: Immunohistochemical staining of 14-
week-old wild-type (WT) and PB-hepsin prostate
glands with anti-hepsin antibodies. Arrows indi-
cate areas of separation between the epithelial
and stromal cell compartment.
F and F: In situ hybridization of ventral prostates
from the 14-week-old animals with antisense hrGFP probe.
G–H: Macroscopic appearance and GFP-imaging of selected urogenital organs from wild-type and PB-hepsin animals. Bladders (BL) with urethras (UR),
seminal vesicles (SV), and anterior (AP) and ventral (VP) prostate lobes were dissected from 20-week-old wild-type (G and H) and PB-hepsin (G and H)
animals. The organs were visualized using visible light (G and G) and GFP fluorescence (H and H). Note prominent GFP fluorescence in the ventral prostate
lobes of PB-hepsin mice.
Bar in E represents 55 m in E–F.
ganization and disruption of the basement membrane in hepsin- To confirm the functionality of the transgenic construct,
expressing prostate glands. To determine the potential role of LNCaP human prostate carcinoma cells were transiently trans-
hepsin in prostate cancer progression, we crossed PB-hepsin fected with the probasin-hepsin (PB-hepsin) plasmid. Western
transgenic animals with mice expressing the SV40 large T anti- blot analysis of total protein extract from hepsin-transfected
gen in the prostate epithelium (LPB-Tag mice, line 12T-7f) cells using anti-hepsin antibodies revealed a 31 kDa band corre-
(Kasper et al., 1998). LPB-Tag animals develop PIN lesions and sponding to the heavy chain of proteolytically processed hepsin
foci of prostate carcinoma; however, primary tumors do not (Figure 1B). Four mouse lines transmitting the PB-hepsin trans-
metastasize. We found that by 21 weeks of age, up to 55% of gene were generated and analyzed. Northern blot hybridization
the double transgenic LPB-Tag/PB-hepsin mice, but none of with hepsin probe revealed that only two lines (C and D) ex-
the single transgenic LPB-Tag or PB-hepsin animals, develop pressed the transgene (Figure 1C). The expression of the trans-
prostate cancer that metastasizes to liver, lung, and bone. These gene was restricted to the ventral lobe of the prostate gland,
data indicate that hepsin promotes primary prostate cancer and it was not detectable in other organs and tissues (Figure
progression and metastasis in the LBP-Tag mouse model of 1D). Similar data were obtained using RT-PCR analysis (data
prostate cancer. not shown, 3 animals were analyzed for each line). Since endog-
enous hepsin expression was not detected in the prostates of
wild-type 10-week-old animals, it is difficult to estimate howResults
the levels of hepsin in our transgenic animals correspond to
the levels of hepsin in human prostate cancer, where hepsinGeneration of transgenic mice expressing
transcripts are upregulated up to 34-fold in comparison to nor-hepsin in prostate epithelium
mal tissue (Stamey et al., 2001).The modified probasin promoter (ARR2PB) is specifically active
Immunohistochemical staining with anti-hepsin antibodiesin prostate epithelial cells in vivo and in vitro and was used for
(n  2) and in situ hybridization with an antisense GFP probeprostate-specific expression of hepsin (Zhang et al., 2000). In
(n 3) demonstrated prostate epithelial cell specific expressionaddition to the promoter, the transgenic construct contains the
of the transgene (Figures 1E–1F). To establish whether the-globin intron, full-length mouse hepsin cDNA, internal ribo-
transgenic construct also expressed functional hrGFP protein,some entrance site (IRES), and humanized renilla GFP (hrGFP)
whole-mount internal organ GFP detection was performed usingcDNA sequences (Figure 1A). This configuration directs the ex-
a dissecting microscope with GFP attachment (Figures 1G–1H).pression of hepsin and hrGFP proteins from the same transcript,
The hrGFP expression was readily detectable in the ventral lobeallowing for convenient monitoring of transcription specificity
by whole-mount internal organ GFP detection (Figures 1G–1H). of prostate gland of the PB-hepsin animals (n  30). Although
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study utilized 4- to 5-month-old mice, a time point before the
manifestation of the massive defects in epithelial-stromal adhe-
sion observed in older animals. To analyze whether the expression
of hepsin in transgenic mice affected the basement membrane,
immunofluorescence staining was performed with antibodies
against the basement membrane markers Laminin 5 (Laminin
 2) and Collagen IV. In wild-type littermates, Laminin 5 staining
appeared as a continuous line separating the stromal and epi-
thelial cell compartments (arrows in Figure 3A, n  5). In con-
trast, Laminin 5 staining in PB-hepsin transgenic mice appeared
weak or completely absent (Figure 3A, n  5). Antibodies
against Collagen IV revealed disorganized and diffuse localiza-
tion of this protein in PB-hepsin prostates (Figure 3B, n 
4). Although the basement membrane displayed normal focal
staining, generally the staining appeared fragmented, with large
sections of the epithelial-stromal interface devoid of Collagen IV.
This pattern of Laminin 5 and Collagen IV localization indicated
a perturbation of the basement membrane in the PB-hepsin
transgenic animals.
One of the major basement membrane receptors expressed
in the prostate epithelium is 64-integrin, which is associated
with hemidesmosomes. Expression of 4-integrin is decreased
in human prostate carcinoma (Bonkhoff, 1998; Davis et al., 2001;
Murant et al., 1997). Immunofluorescence staining with anti-4-
Figure 2. Histologic appearance of ventral prostate lobes from control (WT) integrin antibodies revealed perturbation of the hemidesmoso-
and PB-hepsin (PB-hepsin) animals mal organization in the PB-hepsin prostates. Wild-type mice
Tissue sections were stained with hematoxylin and eosin and examined using displayed a continuous line of 4-integrin staining along the
10 (A and A) and 40 (B and B) objectives. Note separation between basement membrane (arrows in Figure 3C, n  5). In contrast,
epithelial cells and the stromal layer in the PB-hepsin animals (arrows in A
the 4-integrin staining in the transgenic prostate appeared asand B). Bar in B represents 120 m in B and B.
a discontinuous line (Figure 3C, n  5), similar to the “beads
on a string” appearance of 4-integrin in the skin of Laminin
5-deficient mice (Ryan et al., 1999). Taken together, the immu-
nofluorescence staining with markers of the basement mem-GFP fluorescence was visible by whole-mount organ GFP analy-
brane and cell-substratum adhesion structures suggests thatsis, expression was too weak to be detected on frozen tissue
the integrity of the basement membrane is severely compro-sections (data not shown). This enabled us to use the green
mised in PB-hepsin transgenic animals.channel for detection of other proteins in triple immunofluores-
Prostate epithelium contains two major cell populations:cence staining during analysis of the PB-hepsin mice (see
basal cells, which are characterized by the keratin 5/14 expres-below).
sion, and luminal cells, which are characterized by keratin 8/18
expression. To determine whether perturbation of the basementPB-hepsin transgenic mice undergo normal differentiation,
membrane in the PB-hepsin transgenic mice impacted normalproliferation, and apoptosis, but display disorganization
prostate epithelial cell differentiation, we performed immuno-of the basement membrane
fluorescent staining with a variety of cell type-specific markers.Histologic examination of prostates from 3- to 4-month-old ani-
Staining with markers of basal and luminal cells revealed thatmals revealed no obvious abnormalities in the prostate glands
both cell types are present in the PB-hepsin transgenic animalsof PB-hepsin transgenic mice (data not shown). In contrast,
(Figures 3D and 3D). The basal cells represented 12.76 	3 out of 4 one-year-old PB-hepsin, but none of the control,
0.73% of total basal and luminal epithelial cells in the wild-littermates (n  5) displayed separation between the epithelial
type (n  3) and 12.36% 	 1.64% in the PB-hepsin transgenicand stromal cell layers (arrows in Figures 2A–2B). Small areas
animals (n  3). We conclude that upregulation of hepsin inof separation between the epithelial and stromal cell layers were
prostate epithelium did not lead to changes in cell differentiation.occasionally observed in the younger 14-week-old PB-hepsin
Cell-substratum adhesion is important for regulation of cellmice (3 of 7 mice). These areas coincide with the epithelial
proliferation and cell survival. While upregulation of hepsin hadfragments expressing high levels of hepsin (arrows in Figure
no impact on overall size of the prostate gland in the transgenic1E). While it is likely that separation was induced by the fixation
animals (data not shown), it was necessary to determine whetherand sectioning procedures, these results suggest a weakening
hepsin causes differences in proliferation or cell death. To iden-of epithelial-stromal adhesion in the PB-hepsin animals.
tify proliferating cells, immunostaining with anti-Ki67 antibodyThe epithelial and stromal cell compartments of the prostate
was performed. We found that only a very small proportion ofare separated by the basement membrane, which is composed
epithelial cells (0.1%–0.2%) were proliferating in control wild-typeof numerous extracellular matrix proteins produced by both
prostates (Figure 3E, n 3). Upregulation of hepsin had no impactstromal and epithelial cells (Nagle et al., 1995). Since epithelial-
on the number of Ki67-positive cells (Figure 3E, n  3).stromal adhesion is compromised in PB-hepsin mice, we ana-
lyzed localization of cell-substratum adhesion proteins. This To determine whether hepsin overexpression leads to
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Figure 3. Perturbation of the basement membrane, but maintenance of normal differentiation, proliferation, and apoptosis, in the prostate glands of PB-
hepsin transgenic mice
Immunofluorescent staining of ventral prostate glands from 14-week-old wild-type (WT) and PB-hepsin (PB-hepsin) transgenic mice with anti-Laminin 5 (A
and A), anti-Collagen IV (B and B), anti-4-integrin (C and C), and anti-Ki67 (Ki67) (E and E) antibodies, and TUNEL staining for apoptotic cells (F and
F). Double immunofluorescent staining with anti-keratin 5 (Ker5, shown in red) and anti-keratin 8 (Ker8, shown in green) antibodies (D and D). White arrows
in A–C show the position of the basement membrane. DAPI-stained nuclei are shown in blue. The scale bar in F represents 35 m.
changes in programmed cell death, we performed TUNEL stain- hesion between collagen fibers in the basement membrane of
the PB-hepsin animals.ing (Figures 3F and 3F). Few epithelial cells in the wild-type
prostate (0.02%–0.05%) were TUNEL-positive, and these were
usually localized to the lumen of the prostatic acinus (n  3). Hepsin promotes prostate cancer progression
In human prostate cancer progression, disruption of the base-The numbers and localization of apoptotic cells were similar in
the PB-hepsin animals (n 3). We conclude that overexpression ment membrane occurs during the transition from carcinoma
in situ to invasive, metastasizing carcinoma (Abate-Shen andof hepsin in prostate epithelia did not lead to changes in cell
proliferation or apoptotic cell death. Shen, 2000). To determine the significance of hepsin-mediated
disruption of the basement membrane in prostate cancer, we
utilized the LPB-Tag (Line 12T-7f) mouse model of prostateUltrastructural abnormalities in the prostate basement
membrane in PB-hepsin transgenic animals cancer (Kasper et al., 1998). LPB-Tag mice express the SV40
large T antigen (Tag) under the control of the probasin promoter,To determine which part of the epithelial-stromal adhesion sys-
tem is affected in hepsin-expressing prostates, 14-week-old which directs expression of the transgene specifically to the
prostatic epithelium and accessory sex glands. The males oftransgenic animals were analyzed using transmission electron
microscopy (Figures 4A and 4B). Although the overall ultra- this transgenic line develop high-grade PIN and limited foci
of adenocarcinoma at 20 weeks of age, but do not developstructure of prostates from PB-hepsin transgenic mice is similar
to that of the wild-type controls, the organization of the base- metastases. We first analyzed whether endogenous hepsin is
upregulated in the prostate of the LPB-Tag animals. Northernment membrane is consistently affected in the PB-hepsin ani-
mals (Figure 4A). The basement membrane in the wild-type blot analysis with a hepsin probe revealed no detectable endo-
genous hepsin expression in these animals (Figure 5G, n  2).animals contains tightly packed collagen fibers (Figure 4B, n 
2). Microblisters separating the epithelial and stromal cell com- To determine the role of hepsin in prostate cancer, we gener-
ated and analyzed double transgenic LPB-Tag/PB-hepsin mice.partments are abundantly present in the transgenic animals.
High magnification images of the blisters show disruption of The LPB-Tag animals were crossed with the two independently
generated lines of PB-hepsin mice (lines C and D), and doublethe structure at the level of basement membrane (Figure 4B,
n 2). Collagen fibers were present in the basement membrane transgenic LPB-Tag/PB-hepsin males were analyzed at 21
weeks after birth. As previously reported, the LPB-Tag animalsof PB-hepsin prostates; however, the adhesion between the
fibers appears to be compromised. While it is likely that mi- display massive enlargement of the prostate gland. The double
transgenic LPB-Tag/PB-hepsin animals also showed enlarge-croblisters were induced by stress during fixation and sectioning
procedures, the microblistering indicates a failure of proper ad- ment of the prostate that was similar in size and weight to the
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we performed immunofluorescent staining with antibodies rec-
ognizing extracellular matrix proteins. We found that Laminin 5
was absent in both LPB-Tag and LPB-Tag/PB-hepsin prostates
(data not shown). Collagen IV staining was severely reduced in
the hepsin-expressing prostates (Figures 5E and 5E, n  2).
In addition, 4-integrin staining revealed disorganization and
disruption of basement membrane receptors in the LPB-Tag/
PB-hepsin double transgenic animals (Figures 5F and 5F, n 
3). These changes in staining pattern were similar to changes
found in PB-hepsin animals, suggesting hepsin-mediated disor-
ganization of the basement membrane in the LPB-Tag mouse
model of prostate cancer. Since cell-substratum adhesion is an
important source of cell survival signals, the increase in apopto-
sis in the LPB-Tag/PB-hepsin animals may be a consequence of
the disorganization of the basement membrane, which provides
major ligands for cell adhesion receptors.
Hepsin promotes prostate cancer metastasis
Animals from the LPB-Tag 12T-7f line do not display prostate
cancer metastases (Kasper et al., 1998). In contrast, by 21
weeks of age, up to 55% of double transgenic LPB-Tag/
PB-hepsin mice developed prominent metastasis (Table 1, Fig-
ure 6). LPB-Tag/PB-hepsin animals obtained using two inde-
pendently generated PB-hepsin lines developed metastases,
confirming that metastasis was due to hepsin upregulation andFigure 4. Ultrastructural analysis of ventral prostates
not the site of transgene integration. Metastases were observedUltrastructural analysis of ventral prostates from 14-week-old male wild-type
in the liver, lung, and bone of the LPB-Tag/PB-hepsin transgenic(A and B) and PB-hepsin (A and B) transgenic mice. Areas within the
dashed square of A and A are shown at higher magnification in B and B, animals (Table 2). RNA extracted from the livers and lungs of
respectively. The basement membrane in wild-type prostates is structurally LPB-Tag/PB-hepsin mice was positive for PB-hepsin tran-
intact and is tightly packed with collagen fibers (arrow in B). Transgenic
scripts (Figure 6B). In addition, PB-hepsin mRNA was detectableprostates display microblisters at the basement membrane (shown with
in the bone metastases by in situ hybridization (Figure 6I, n asterisk in B). BM, basement membrane; SM, smooth muscle cell in the
stromal cell compartment; LC, luminal cell; BC, basal cell. Bar in B represents 2). These data demonstrate active hepsin expression in the
1 m in B and B, and 7 m in A and A. metastatic lesions. Immunohistochemical analysis demon-
strated that metastases were also positive for androgen receptor
and SV40 large T antigen, confirming their prostatic origin
(arrows in Figures 6J and 6L, n  4). Metastatic lesions in
prostates from LPB-Tag animals (data not shown). Histologic other SV40 T antigen-driven mouse models of prostate cancer
examination of prostate glands from LPB-Tag animals revealed (TRAMP, CR2-T-Ag, LPB-Tag line 12-T10) display features of
typical PIN-like lesions and stromal cell hyperplasia (Figures 5A NE differentiation (Shappell et al., 2004). Morphologically, me-
and 5B, n  15). The prostate glands from the LPB-Tag/PB- tastases in LPB-Tag/PB-hepsin animals contained tightly
hepsin animals display areas showing disruption and disorgani- packed cells displaying nuclear molding and high nuclear/cyto-
zation of epithelial structure (Figures 5A and 5B, n  26). In plasmic ratio that was consistent with features of NE differentia-
addition to PIN-like lesions, prostates from LPB-Tag/PB-hepsin tion. Moreover, these metastatic lesions were positive for synap-
double mutant mice typically showed adenocarcinoma with ex- tophysin, a marker of NE cells, confirming their NE differentiation
tensive glandular differentiation and focal areas of “punched (Figure 6K, n  4). Overall, we conclude that upregulation of
out,” cribriform lesions. Often, the neoplastic glands invaded hepsin in a mouse model of prostate cancer resulted in marked
the periprostatic stroma (arrow in Figure 5B). In half of the progression of prostatic tumors and caused the development
analyzed double transgenic mice, the tumor cells showed nu- of NE metastatic tumors to the liver, lung, and bone.
clear and chromatin patterns as well as architectural features
including “rosette formation” that suggested neuroendocrine Discussion
(NE) differentiation (arrowhead in Figure 5B). These changes
were not due to the differences in the levels of SV40 T antigen, The metastatic cascade is a complex process consisting of a
which were found to be similar between the LPB-Tag and LPB- number of important steps that include loss of tissue architec-
Tag/PB-hepsin prostates (Figure 5H). ture, local invasion, invasion into blood and lymph vessels, ex-
Staining with Ki67 antibodies revealed no difference in cell travasation, establishment of the secondary foci, and angiogen-
proliferation between the prostates of LPB-Tag and LPB-Tag/ esis (Robinson et al., 2004). Failure to complete any of these
PB-hepsin animals (Figures 5C and 5C, I, n  3). In contrast, steps would result in the absence of metastases. The classic
TUNEL staining showed a 4-fold increase in apoptosis in the model of the metastatic process assumes that metastases arise
double transgenic animals (Figures 5D, 5D, and 5J, n  4). from the rare cells that, in addition to the early oncogenic alter-
To determine whether hepsin expression causes changes ation enabling them to form primary tumor, subsequently accu-
mulated novel mutations that promote metastasis.in the organization of the basement membrane in this model,
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The recently proposed alternative model suggests that com-
bination of early oncogenic alterations in the primary tumor
determines its metastatic potential (Bernards and Weinberg,
2002). We have found that hepsin has no impact on cell prolifera-
tion and, therefore, it does not act as a classic oncogene. In
contrast, increase in hepsin expression leads to disorganization
of the basement membrane and promotes primary prostate
cancer progression and metastasis. These hepsin functions are
consistent with the classic model of metastatic process. On the
other hand, the fact that hepsin becomes upregulated very early
in the human prostate cancer at the stage of PIN-like lesions is
more in line with the alternative model of metastasis. Therefore, it
appears that our findings provide some support for both models.
It is possible that some middle ground may exist between these
seemingly opposing views of metastatic process.
The basement membrane is a specialized extracellular ma-
trix structure that separates the epithelial and stromal cell com-
partments. Loss of the basement membrane is a mandatory
step that occurs during local invasion early in the metastatic
process (Abate-Shen and Shen, 2000; Robinson et al., 2004).
To accomplish local invasion, tumor cells use extracellular and
cell surface proteolytic enzymes to degrade the basement mem-
brane proteins (Chang and Werb, 2001; Del Rosso et al., 2002).
Multiple studies have demonstrated a critical role of matrix met-
alloproteinases (MMPs) that can degrade the extracellular matrix
and basement membrane proteins and facilitate the initial inva-
sion events (Chang and Werb, 2001). Simple inhibition of MMPs,
however, is not necessarily beneficial for cancer patients’ out-
come. The roles of MMPs are quite complex, as they have
functions other than promotion of metastasis and have sub-
strates other than extracellular matrix proteins (Egeblad and
Werb, 2002). The second, perhaps equally important, group of
enzymes involved in degradation of the extracellular matrix and
modulation of cell-substratum adhesion is the family of serine
proteases (Del Rosso et al., 2002). One of the best-studied
serine proteolytic systems at the cell surface is the urokinase-
type plasminogen activator (u-PA) and u-PA receptor (u-PAR).
The u-PA/u-PAR complex has an intrinsic ability to concurrently
regulate pericellular proteolysis and cell surface adhesion re-
ceptors.Figure 5. Hepsin causes disruption of epithelial structure and promotes can-
cer progression in the SV40 T antigen-driven mouse model of prostate We present here in vivo evidence that upregulation of type-
cancer II cell surface serine protease hepsin leads to disorganization
A–B: Histologic appearance of ventral prostates from 21-week-old LPB-Tag and disruption of basement membrane.
and LPB-Tag/PB-hepsin animals. Note disorganization of epithelial structure, Since hepsin is a serine protease, it is likely that it exercisesadenocarcinoma with glandular differentiation, and foci of poorly differen-
its function through proteolytic digest of specific substrate pro-tiated NE adenocarcinoma (arrowhead in B) in LPB-Tag/PB-hepsin animals.
C and C: Immunostaining with anti-Ki67 antibodies shows no differences teins. If some of these substrates are the basement membrane
in cell proliferation between LPB-Tag and LPB-Tag/PB-hepsin animals. proteins, hepsin may be directly involved in degradation of the
D and D: Apoptosis is increased in the prostates of LPB-Tag/PB-hepsin mice. extracellular matrix. Alternatively, hepsin may activate other pro-
Apoptotic cells were detected using TUNEL staining (green).
teases that are often synthesized as nonactive proenzymes.E and E: Decreased staining for Collagen IV in LPB-Tag/PB-hepsin mice
By this means, it can activate a proteolytic cascade that will(green).
F and F: Immunostaining with anti-4-integrin antibodies (red) reveals disor- ultimately lead to degradation of the extracellular matrix pro-
ganization of basement membrane receptors in LPB-Tag/PB-hepsin mice teins. Experiments with cultured cell lines demonstrated that
(arrows).
G: Endogenous hepsin is not upregulated in the prostate of LPB-Tag mice.
RNA was extracted from ventral prostates of wild-type, PB-hepsin, and LPB-
Tag animals and analyzed by Northern blot hybridization with hepsin and
GAPDH probes.
J: Quantitation of experiments shown in D and D. Number of TUNEL
 cellsH: Absence of changes in the levels of T-antigen (Tag) in LPB-Tag/PB-hepsin
animals. Proteins from ventral prostates of PB-hepsin, LPB-Tag, and LPB-tag/ per total cell numbers was counted. Note that staining with FITC-labeled
secondary antibodies was possible because hrGFP fluorescence was tooPB-hepsin animals were analyzed by Western blotting with anti-Tag and
anti--actin antibodies. weak to be detected on frozen tissue sections (data not shown).
The scale bar in F represents 66 m for frames A and A, and 33 m forI: Quantitation of the experiments shown in C and C. Proliferation index
determined as a ratio of proliferating cells (Ki67
) to the total cell number. B–F.
190 CANCER CELL : AUGUST 2004
A R T I C L E
SP1, a close relative of hepsin, has been shown to activateTable 1. Incidence of metastasis in LPB-Tag, PB-Hepsin, and LPB-Tag/PB-Hep-
sin animals PAR-2 and pro-u-PA (Takeuchi et al., 2000).
Overexpression of hepsin in metastases-derived humanTotal # # of mice
Genotype of mice with metastasis prostate cancer cell lines decreases their ability to invade Lami-
nin 1-based Matrigel (Srikantan et al., 2002). This appears toLPB-Tag 15 0
contradict our findings with in vivo overexpressed hepsin. WhilePB-Hepsin lines C and D 9 0
LPB-Tag/PB-Hepsin line C 12 5 the in vitro invasion system is capable of deciphering the differ-
LPB-Tag/PB-Hepsin line D 20 11 ences in the Matrigel degradation abilities, it cannot assay the
21-week-old mice with indicated genotypes were analyzed by hematoxylin initial stages of invasion that include disruption of normal epi-
and eosin staining and microscopy. By 21 weeks of age, 55% of LPB-Tag/ thelial structure, weakening of cell-substratum adhesion, and
PB-hepsin line D and 42% of LPB-Tag/PB-hepsin line C animals developed failure of basement membrane deposition and assembly. Ourmetastases. All LPB-Tag and PB-hepsin mice analyzed were free of metasta-
results demonstrate that hepsin overexpression causes disorga-sis. The differences in metastasis formation between LPB-Tag versus LPB-Tag/
PB-hepsin line D and LPB-Tag versus LPB-Tag/PB-hepsin line C animals were nization of the basement membrane and, therefore, is likely to
statistically significant, with P values of 0.006 and 0.03, respectively. act at the early stages of metastatic pathway. Future experi-
ments will help to determine the substrates for hepsin proteolytic
activity that may be responsible for its function in disorganization
of the basement membrane.
The type II serine proteases have been previously implicatedblood coagulation factor VII may be one of the hepsin proteolytic
in cancer progression (Del Rosso et al., 2002; Netzel-Arnett etsubstrates (Kazama et al., 1995). Hepsin can convert factor VII
al., 2003; Wu, 2003). The supporting evidence, however, hasto VIIa and activate the blood coagulation cascade leading to
been mostly circumstantial. Many of these proteins are upregu-formation of thrombin, deposition of pericellular fibrin, and acti-
lated in cancer. For example, corin is upregulated in leimyosar-vation of PAR-1. Other type II serine proteases have also been
demonstrated to be able to activate proteolytic cascades. MT- coma, endometrial carcinoma, and osteosarcoma (Yan et al.,
Figure 6. Hepsin promotes metastasis in the LPB-Tag mouse prostate cancer model
A: Macroscopic appearance of livers from 21-week-old LPB-Tag and LPB-Tag/Hepsin animals. Extensive metastasis was observed in double transgenic
mice.
B: PB-hepsin transgene expression in prostate metastases to liver and lung from LPB-Tag/PB-hepsin animals. RNA extracted from various organs of LPB-Tag
and LPB-Tag/PB-hepsin animals was subjected to RT-PCR analyses with primers specific for PB-hepsin (Hepsin-IRES-GFP) or control GAPDH transcripts. Samples
without RT served as controls.
C–H: Histologic appearance of liver (C and D), lung (E and F), and bone (G and H) showing prominent metastases in the LPB-Tag/PB-hepsin mice. Areas
within dashed squares of C, E, and G are shown at higher magnification in D, F, and H, respectively.
I–L: Bone metastases in LPB-Tag/PB-hepsin animals are positive for PB-hepsin transgene (Hepsin-IRES-GFP), T-antigen (Tag), synaptophysin (Syn), and androgen
receptor (AR) expression. PB-hepsin transgene expression was determined by in situ hybridization (I). Expression of T antigen, synaptophysin, and androgen
receptor was revealed by immunohistochemistry (J–L). The scale bar in L corresponds to 0.5 mm in C, E, and G, 0.3 mm in J–L, 150 m in I, and 50 m in
D, F, and H.
CANCER CELL : AUGUST 2004 191
A R T I C L E
Table 2. Distant organs displaying metastasis in the LPB-Tag/PB hepsin mice
Organs displaying metastasis
Genotype of mice with
metastasis Animal # Liver Bone Lung Kidney Spleen
LPB-Tag/PB-hepsin line C 41 














LPB-Tag/PB hepsin line D 29 
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138 
    
151 
    
21-week-old animals were analyzed as described in the legend for Table 1. Only the data for animals with metastasis are shown.
1999). The TMPRSS2 and TMPRSS4 are overexpressed in pros- to disrupt the basement membrane and facilitate initial tumor
tate and pancreatic cancers, respectively (Lin et al., 1999; Wall- cell spreading, but may not cause complete loss of substratum
rapp et al., 2000). Finally, hepsin was found to be overexpressed adhesion and subsequent cell death.
in prostate and ovarian cancers (Chen et al., 2003; Dhanasek- Human prostate cancer metastasizes preferentially to bone.
aran et al., 2001; Ernst et al., 2002; Luo et al., 2001; Magee et The mechanisms responsible for bone metastasis are not
al., 2001; Stamey et al., 2001; Stephan et al., 2004; Tanimoto known. Bone metastases are extremely rare in the current
et al., 1997; Welsh et al., 2001). Injections of inhibitors of type mouse models of prostate cancer. Paucity of bone metastases
II serine proteases suppress primary tumor growth and metasta- has been one of the major limitations of mouse models of pros-
sis of human PC3 prostate tumor cells implanted into nude mice tate cancer. We demonstrate that, unlike human prostate epithe-
(Takeuchi et al., 1999). Tumor cells overexpressing the type II lial cells, mouse prostate epithelium does not express detect-
serine protease matriptase show higher incidence of metastasis able levels of endogenous hepsin. Exogenous transgene
when they are injected into nude mice (Ihara et al., 2002). expression of hepsin was sufficient to promote prostate cancer
The role of hepsin in prostate cancer has been a matter of metastasis to the bone, as up to 24% of 21-week-old LPB-Tag/
debate. While all studies agree that hepsin is upregulated in PB-hepsin double transgenic animals exhibited bone metasta-
human prostate cancer, it is not clear how hepsin expression ses. It is important to note that these numbers are likely to be
levels correlate with patient outcome. While initially it was found an underestimation, since only the femur bones, representing
that hepsin levels inversely correlate with the recurrence of pros- only a small fraction of total bone mass, were analyzed in this
tate cancer (Dhanasekaran et al., 2001), a later study revealed study. The bone lesions in the LPB-Tag/PB-hepsin animals do
a positive correlation (Stephan et al., 2004). Hepsin overexpres-
not show obvious osteoblastic or osteolytic characteristics. This
sion in metastases-derived prostate cancer cell lines decreases
is different from human prostate cancer bone metastases that
their rates of proliferation (Srikantan et al., 2002). Since we found
often show osteoblastic characteristics.that wild-type mouse prostate epithelial cells do not express
Similar to metastatic lesions in other SV40 T antigen-drivenendogenous hepsin, it is very difficult to estimate how levels of
mouse models of prostate cancer, metastases in the LPB-Tag/hepsin expression in our transgenic mice compare to hepsin
PB-hepsin animals express NE markers. At present, it is notupregulation in human prostate cancer. The level of expression
known whether NE markers in these lesions reflect their NEmay play a very important role in the phenotype. If hepsin is
origin, or they emerge during metastatic process as a conse-involved in degradation of cell-substratum adhesion proteins
quence of epithelial to NE transdifferentiation that may beand its activity is very high, prostate epithelial cells will not be
caused by expression of SV40 T antigen. Since hepsin promotesable to maintain substratum adhesion, and will separate from
prostate cancer progression by disorganization of the basementthe basement membrane or tissue culture surface and undergo
membrane, and disruption of the basement membrane occursapoptosis. While extracellular matrix degradation is beneficial
in both NE and non-NE types of prostate cancer, it is likely thatand sometimes absolutely necessary for initial tumor invasion, it
hepsin will promote metastasis in the mouse models that domay be less advantageous during the later stages of metastasis
not develop NE differentiation markers. This will be addressedformation, where ability to form de novo attachment in distant
experimentally in our future studies.organs is necessary for metastatic cell survival. It is possible
Since hepsin promotes prostate cancer progression andthat very high levels of hepsin expression, which are found in
metastasis, specific inhibition of hepsin proteolytic activity maya subset of human prostate cancers, may indeed be associated
be effective in blocking prostate cancer progression in humanwith inhibition of cell growth and better patient survival progno-
sis. However, moderate levels of upregulation may be sufficient patients. Hepsin knockout mice have no phenotype (Wu et al.,
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the Trizol reagent from Gibco. PCR-generated full-length mouse hepsin1998), suggesting that specific inhibition of hepsin in human
cDNA and GAPDH probes were used as probes for Northern blot analysis.patients will not have significant side effects.
In situ hybridization was performed on paraffin sections as described pre-In summary, our in vivo studies have revealed a critical
viously (Fijnvandraat et al., 2002). The digoxygenin-labeled antisense hrGFProle for hepsin in disruption of the basement membrane and
RNA was synthesized using the kit from Roche. The RT-PCR analyses were
promotion of adenocarcinoma and metastasis in a mouse model performed using the kit from Invitrogen. Primers 5-AGGAGATCATGAGCTT
of prostate cancer. These findings identify hepsin as a metasta- CAAGG-3 and 5-GCTGTAGAACTTGCCGCTGT-3 were used to amplify the
sis-promoting protein and suggest that it may provide a thera- transgenic transcript. Primers 5-CATGTGGGCCATGAGGTCCACCAC-3 and




Plasmids For immunofluorescent staining, tissues were embedded in OCT and then
Generation of PB-IRES-hrGFP transgenic construct frozen immediately on dry ice. The 7 m cryosections were subjected to
The ARR2PB synthetic probasin promoter (Zhang et al., 2000) was indirect immunostaining and analyzed using the Nikon TE 200 microscope
KpnI(blunted)/SacI digested and subcloned into the NsiI (blunted) and SacI
equipped with COOLSNAP HQ digital camera or using the Applied Precision,
sites of the pIRES-hrGFP-2a vector (Stratagene). The -globin intron se-
Inc. Delta vision SA3.1 Deconvolution Microscope. In some cases, tissuesquence from the K14 expression construct (Vasioukhin et al., 1999) was
were first processed, embedded in paraffin, and sectioned, and resultingAvaI (blunted)/NotI digested and subcloned into the SpeI (blunted) and NotI
sections were deparafinized, rehydrated, and processed as describedsites of the ARR2PB-pIRES-hrGFP-2a backbone. The MCS in the pBluescript
above. The ABC elite or ABC MOM kits (Vector Laboratories) were used forII KS vector (Stratagene) was modified by SacI/PstI digestion and ligation
immunohistochemistry. Antibodies were detected with a DAB peroxidaseof oligos encoding the MluI and AscI sites. The ARR2PB--globin-hrGFP-
substrate kit and sections were counterstained with hematoxylin QS (both2a-SV40 polyA fragment was ClaI/MluI (partial) digested and subcloned into
from Vector Laboratories).the ClaI and MluI sites of the modified pBluescript vector. The resulting PB-
IRES-hrGFP vector contained the ARR2PB promoter to direct expression to
Antibodies and apoptosis stainingprostate epithelium, the -globin intron to increase the levels of the transcript,
the multiple cloning site with unique SpeI, NotI, SrfI, XmaI, EcoRI, and SphI Antibodies used: anti-hepsin (Cayman Chemical), anti-Collagen I and III
cleavage sites for cloning the desired insert, the IRES-hrGFP sequences to (Rockland), anti--actin (Sigma), anti-Laminin 5 (3/2 chains), anti-Laminin
reinitiate the translation of the reporter hrGFP from the same transcript, and 1(1/1 chains), anti-fibronectin, anti-4-integrin (Dr. William Carter,
the SV40 polyadenylation sequence to stabilize the mRNA. FHCRC), anti-Ki67 (Novacastra Laboratories), anti-keratin 8, anti-Collagen
Generation of the PB-hepsin transgenic construct IV (Developmental Studies Hybridoma Bank), anti-keratin 5 (Vasioukhin et al.,
The full-length mouse hepsin cDNA was PCR amplified from the IMAGE 2001), anti-synaptophysin (Zymed Laboratories), anti-SV40 T-Ag (Oncogene
clone #747832 using the primers containing the SpeI and EcoRI sites Research Products), anti-androgen receptor (N-20, Santa Cruz Biotechnol-
(5GCACTAGTATGGCGAAGGAGGGTGGCC3 and 5GCGAATTCTCAGG ogy). Relevant FITC- or Texas Red-conjugated donkey or goat antibodies
GCTGAGTCACCATG3). The resulting 1.25 kB fragment was cloned into (Jackson Laboratories) were used for detection of primary antibodies. Apo-
the SpeI and EcoRI sites of the PB-IRES-hrGFP vector. The PCR-generated ptosis was determined using the FragEL kit from Oncogene Research.
hepsin cDNA was verified by sequencing.
Quantitation of cell differentiation, proliferation, and apoptosis
Mice
For quantitation of data obtained using the immunofluorescent stainings,The PB-hepsin fragment was obtained by ClaI/AscI digestion, purified, and
similar areas in the prostates of the PB-hepsin, LPB-Tag, PB-hepsin/LPB-injected into fertilized C57BL/6JxCBA mouse eggs. The eggs were trans-
Tag, and wild-type animals were selected, and total number of cells andplanted into pseudopregnant females (FHCRC transgenic facility). The re-
cells stained positive with indicated antibodies were counted.sulting mice were screened by PCR with primers used for amplification of
the hepsin cDNA in the PB-hepsin plasmid construct (see above). Founder
Statistical analysisPB-hepsin mice were bred with C57BL/6J animals and the resulting lines
Fisher’s exact test was used to compare the metastases data between thewere maintained on the C57BL/6J genetic background.
LPB-Tag and LPB-Tag/PB-hepsin animals.The LPB-Tag mice (line 12-T7f) have been previously described (Kasper
et al., 1998). This transgenic line was maintained by breeding with CD-1
animals. LPB-Tag/PB-hepsin double transgenic mice were generated by Acknowledgments
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